Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD). The reported incidence varies between 0.5% and 4.4% and increases with length of time on PD. Very few data are available on the epidemiology of EPS in the United States. The aim of the present study was assess the incidence of EPS in a single center in New Haven, Connecticut. In a retrospective analysis of all patients maintained on PD for 5 or more years, clinical symptoms were documented, abdominal computed tomography (CT) findings were reviewed, and surgical and pathology findings were noted. Patients were tracked whether they remained on PD, transferred to hemodialysis (HD), underwent transplantation, or died. Among the 76 patients that met the inclusion criteria (mean dialysis duration: 81.5 ± 22 months), 14 (18%) developed clinical symptoms (persisting for 3 or more months) suggestive of EPS. Abdominal CT imaging was done in 38 patients; 25 had radiologic features consistent with EPS. At laparotomy, 6 of 7 patients had gross findings consistent with EPS. Eleven patients met the 2000 criteria of the International Society for Peritoneal Dialysis for a diagnosis of EPS; they had clinical features, plus either radiologic or histopathologic confirmation. In 3 patients with clinical symptoms, the radiologic or surgical findings did not support a diagnosis of EPS. Of the 11 patients meeting the EPS criteria, 1 remains on PD and is doing well, 2 were transferred to HD and are doing well, 2 died as a result of EPS complications, and 6 died of other causes. The present study suggests that, in patients maintained on PD for 5 or more years at our center, the incidence of EPS is 14%. Those findings suggest that EPS may be underrecognized in the United States and that a high index of suspicion is warranted in patients maintained on PD for 5 or more years. 
P eritoneal dialysis (PD) is generally accepted as a viable therapy for patients with end-stage renal disease (ESRD). Recent studies have suggested that, compared with ESRD patients maintained on hemodialysis (HD), patients maintained on PD have a lesser relative mortality rate for the initial 1 -2 years of therapy (1) . That relative risk changes over time, with the risk increasing for PD patients, raising some concerns about the use of PD for long-term therapy (2) . One of those concerns involves the potential risk for encapsulating peritoneal sclerosis (EPS), a serious but uncommon complication of PD (3), first described in 1980 (4) .
Encapsulating peritoneal sclerosis is characterized by a progressive intra-abdominal inflammatory process, resulting in sheets of fibrous tissue that cover, bind, and constrict the viscera, compromising the motility and function of the bowel (3) . The result can be a prolonged, debilitating illness, with an estimated associated mortality rate of 56% (5) . In a series of studies from a variety of countries, the incidence of EPS has been reported to vary between 0.54% and 4.4% (3, (5) (6) (7) (8) (9) (10) . The incidence rises as time on PD increases, especially in patients maintained on PD for more than 5 years. Registry data suggest that the percentage of patients developing EPS after 5 years of PD therapy is between 2% and 8% (3, 6) . However, the criteria used to diagnosis EPS from registry data are not always clear (3) . Very few data are available on the incidence of EPS in the United States.
The aim of the present study was to make an assessment of the incidence of EPS in a single large PD program in the United States, with a focus on patients maintained on PD for 5 or more years. For diagnosing EPS, the study applied the standardized criteria (10) established by the International Society of Peritoneal Dialysis (ISPD).
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METHODS
All patients who started PD at the New Haven continuous ambulatory peritoneal dialysis unit (New Haven CAPD) from 1988 through 2003 and who were maintained on PD for 5 or more years were identified (n = 76). During that period, 1100 patients were trained by New Haven CAPD. The operation and functioning of New Haven CAPD have previously been described (11) . All patients were using standard Dianeal dialysis solutions (Baxter Healthcare Corporation, Deerfield, IL, USA). Dextrose concentrations were adjusted by the patients to maintain volume control; full records were not kept of the dextrose concentrations actually used by the patients over the years of the study.
All patients who were currently on PD treatment and who had been on treatment for 5 or more years (n = 14) were noted, and their status at study end (August 2008) was reviewed. The records of patients who had died were obtained and reviewed (n = 25). The status of patients on PD for 5 years or more who then were transplanted (n = 16) or transferred to HD (n = 21) were noted, and their charts were reviewed.
We obtained data concerning possible symptoms of EPS, the most recent computed tomography (CT) images of abdomen and pelvis that had been performed after 5 years of PD therapy, and any surgical and pathology findings noted at times of exploratory laparotomy performed for any reason after 5 years of PD therapy.
Following the ISPD guidelines from 2000 (10), a diagnosis of EPS was made when there was strong clinical suspicion (based on the clinical criteria described in the next subsection) that was confirmed by either radiologic findings (described on CT imaging) or pathology findings (described at the time of surgical exploration).
CLINICAL CRITERIA Symptoms considered to be consistent with EPS have recently been reviewed (12) . We specifically looked for abdominal pain, nausea, vomiting, diarrhea, anorexia, and progressive unintentional weight loss as documented by monthly reports and progress notes. If these gastrointestinal (GI) symptoms were reported by patients for 3 months or more, the chart and any referral or hospital records (if available) were further reviewed to ensure that alternative explanations for the symptoms had not been noted. Only then were the symptoms attributed to possible EPS. In addition, findings of sterile peritoneal inflammation and hemoperitoneum were documented. RADIOLOGIC 
CRITERIA
The relevant CT images were obtained and reviewed. For patients whose most recent study was only in the form of physical films, the films were examined on a viewbox; the remaining studies were viewed on a picture archiving and communication system workstation. It was primarily axial images that were reviewed; multilayer sagittal and coronal reformatted images were examined when necessary. All images were interpreted by 2 readers: 1 radiology resident with 3 years' experience, and 1 attending radiologist with 15 years' experience in body imaging. Findings of the imaging review were scored according to the grading system proposed by Tarzi et al. (13) .
The findings recorded and graded were these: Images were reviewed with blinding to the grouping of each patient. Consensus was achieved on all items during simultaneous review of the images by both readers.
PATHOLOGY CRITERIA Surgical notes were reviewed for all patients who underwent exploratory surgery for any reason after 5 years of PD therapy. Gross findings considered to be consistent with EPS included adherent intestinal loops, thickened visceral peritoneum, and cocoon formation (14) . Histology findings indicative of EPS included fibrin deposition, fibroblast swelling, capillary angiogenesis, and mononuclear cell infiltration (15) .
STATISTICS
Only incident patients who started PD after 1 January 1988 and who had been maintained on PD for 5 or more years were used in the calculation of EPS incidence.
The incidence of EPS was calculated as the number of EPS cases divided by number of patients at risk (16) . Peritonitis rates were calculated as the number of episodes of peritonitis divided by the total number of months on PD therapy. The Student t-test was used to compare mean values.
RESULTS
DEMOGRAPHICS
Seventy-six patients had been maintained on PD for 5 years or more (Table 1) . Their mean age at dialysis start was 54 ± 18 years (range: 19 -88 years), 40 (53%) were male, 39 (51%) were Caucasian, and 20 (26%) had diabetes. The mean duration on PD was 81.5 ± 22 months (range: 60 -157 months). The most common causes of ESRD were glomerulonephritis (33%) and hypertension (28%).
At the end of the study, 14 patients remained on PD, 21 had transferred to HD, 16 had undergone transplantation, and 25 had died.
CLINICAL FEATURES
Clinical symptoms for which there was no obvious explanation and which persisted for more than 3 months were noted in 14 patients (18%, Table 2 ). Those symptoms included nausea (13%), vomiting (13%), diarrhea (6.5%), anorexia plus weight loss (6.5%), and abdominal pain (2.6%). No patients were noted to have sterile peritoneal inflammation or hemoperitoneum. No patients were treated with antifibrotic agents or antiinflammatory agents.
RADIOLOGIC FEATURES IN PATIENTS WHO UNDERWENT CT IMAGING
Abdominal CT images were obtained in 38 patients for a variety of reasons. In 25, radiologic features suggestive of a diagnosis of EPS were present. The most common findings included bowel wall thickening (16 patients), loculated fluid (14 patients), bowel tethering (14 patients), and peritoneal thickening (12 patients). Peritoneal calcification and bowel dilatation were seen in 7 and 6 patients respectively.
PATHOLOGY FEATURES
Exploratory laparotomy was performed in 7 patients because of peritonitis, abdominal abscess, acute abdomen, or small-bowel obstruction. In 6 of the 7, findings were consistent with EPS (described as matting of bowel, dense or thickened peritoneum, or cocoon formation).
DIAGNOSIS OF EPS
Eleven patients (14.5% of those maintained on PD for 5 or more years) met the ISPD criteria for a diagnosis At the time of the study, 3 patients were still on PD, and 8 were on HD. None of the patients who had undergone transplantation met the criteria for a diagnosis of EPS. The 8 patients who transferred to HD did so because of recurrent peritonitis (n = 3), ultrafiltration failure (n = 1), psychosocial issues (n = 1), other medical reasons (n = 2), and concerns about a diagnosis of EPS (n = 1).
PERITONITIS
The overall peritonitis rate of the unit during the study period was 1 episode in 23 patient-months. In the 11 of EPS. Of 14 patients with clinical symptoms, 3 did not have radiologic or surgical findings that supported a diagnosis of EPS. The cause of the GI symptoms in those 3 patients is uncertain. Of 25 patients with radiologic findings suggestive of EPS, 10 had clinical findings to support the diagnosis (Table 3 ). The other 15 did not have clinical findings of EPS at the time of CT imaging or on subsequent follow-up.
RADIOLOGIC FINDINGS IN PATIENTS WITH EPS
We examined the CT images to try to distinguish patients with clinical findings of EPS from those without such clinical findings. Patients were arbitrarily divided into those having Tarzi scores of 2 or higher for 3 or more of the 6 radiologic findings suggestive of EPS (3), and those having a score of 2 or higher for fewer than 3 of the 6 findings. Scores of 2 or higher for 3 or more of the 6 radiologic findings were observed in 50% of the patients with clinical findings of EPS, but in only 13% of the patients without such clinical findings. Among EPS patients, the peritonitis rate was 1 episode in 15.3 patient-months (p = 0.006). As previously described for our unit (11), the spectrum of organisms causing peritonitis was not different in the EPS patients and in the other patients treated at the facility. Table 4 sets out the frequency of episodes of peritonitis in the patients who developed EPS.
OUTCOMES
Of the 11 EPS patients, 1 remains on PD (5.5 years on PD therapy) and is clinically stable; 2 died while on PD from causes not related to EPS (1 secondary to sepsis from pneumonia, 1 from cardiac arrest). The remaining 8 patients transferred to HD for various reasons, as noted earlier. All patients had clinical symptoms suggestive of EPS before transfer. Of those 8 patients, 2 died from complications attributed to EPS. Another 2 are alive and doing well on HD; the remaining 4 died of non-EPSrelated causes.
DISCUSSION
The diagnosis of EPS can be challenging, and the criteria used to establish the diagnosis in various studies are not always clear. In the present study, we used the criteria outlined by the ISPD in 2000, which include the presence of clinical symptoms and either radiologic or surgical confirmation of the diagnosis. It is a challenge for the clinician to decide whether GI symptoms are the result of EPS or of other disorders.
The chronic, often insidious, nature of the GI symptoms, without other obvious causes, is characteristic of EPS. We attributed clinical symptoms to EPS only if those symptoms were present for a minimum of 3 months and if other obvious explanations were lacking. The radiology findings tracked in the present study were those outlined by Tarzi et al., including a standardized scoring system of peritoneal calcifications, peritoneal thickening, presence of loculated fluid, bowel wall thickening, tethering of the bowel wall, and bowel dilatation. The pathology findings in EPS have been well described. Although those findings may overlap with the membrane changes that occur in long-term PD, with ultrafiltration failure and infectious peritonitis (15, 17) , it is the extent of disease that characterizes EPS.
In the present study from a single center in North America, we found that 11 patients (14.5%) among those maintained on PD for 5 or more years developed findings consistent with EPS. Clinical GI symptoms with no obvious cause were present in 14 patients, but only 11 of those patients met the ISPD criteria for EPS. The reasons for the GI symptoms in the other 3 patients are not clear; the patients did not have the radiologic or surgical criteria for EPS. But in all 11 of the patients with clinical symptoms consistent with EPS, confirmation was made radiologically (n = 10) or pathologically (n = 5), or both. The presence of CT abnormalities in 25 patients (66%) with available CT imaging is striking. But only 10 of those 25 patients had clinical findings suggestive of EPS; 15 patients lacked such clinical findings and did not develop EPS on follow-up. Those observations underscore the importance of using the ISPD criteria-that is, the presence both of clinical findings and of either radiologic or surgical findings-to diagnosis EPS.
The clinical significance of the positive findings on CT imaging in the absence of clinical symptoms remains uncertain, underscoring the importance of cautious interpretation of CT findings in this patient population, as emphasized by Tarzi et al. (13) . It is noteworthy that, in the EPS patients, radiology findings in 50% were positive for 3 of 6 categories; by contrast, only 13% of patients without EPS showed such findings. Moreover, the most dramatic differences noted between the groups were those relating to peritoneal and bowelwall thickening.
The seemingly high proportion of patients who developed EPS after 5 years on PD in the present study accords with recently reported results from the Scottish Renal Registry (12) . In the study from Scotland, the EPS incidence increased with PD duration, with rates of at least 8% after 4 -5 years of PD exposure (12) . More recently, data from the Australia-New Zealand database suggest an EPS incidence of 3.9% for patients maintained on PD for 8 years (6). However, in both of the foregoing studies, the data were obtained from registry information and not from a single center using pre-determined criteria to confirm a diagnosis. A single-center study from the United Kingdom (18) reported an EPS incidence of 3.3% (27 of 810 patients managed between 1998 and 2003). The mean duration of PD therapy among patients developing EPS was 72.6 ± 39.7 months (18). The actual incidence of EPS in patients on PD for 5 or more years was not reported, but the authors of that study emphasized the importance of using abdominal CT imaging to screen patients who have been on PD for more than 5 years (18).
What are the factors associated with the development of EPS? Several have been suggested to perhaps predispose patients to EPS (7, 8, 10, (19) (20) (21) (22) (23) (24) .
Encapsulating peritoneal sclerosis has been reported to develop after cessation of PD and transplantation or transfer to HD. Cases of EPS occurring after kidney EPS: A SINGLE-CENTER EXPERIENCE transplantation have been well described (19) (20) (21) (22) . Those occurrences have been hypothesized to be secondary to the transplantation procedure itself, to the use of immunosuppressive agents with profibrotic properties (such as the calcineurin inhibitors), or to other poorly defined factors (22) . Notably, none of the patients in our study who had been on PD for more than 5 years and who underwent transplantation developed EPS (mean duration of follow-up post transplant was 56 months). The 2 patients who received a graft and who had GI symptoms both had negative CT imaging within the first year post-transplant, and thus did not meet the criteria for a diagnosis of EPS. The reasons that patients in the present study did not develop EPS post transplant, as has occurred in other studies, is not clear (19) (20) (21) (22) . Encapsulating peritoneal sclerosis has also been reported to develop after PD has been stopped, with transfer of the patients to HD. In one study in Japan, 68% of EPS cases occurred after PD had been stopped and the patient had been transferred to HD (7) . In the present study, no patient developed EPS after transfer to HD, and all 8 patients who transferred had symptoms of EPS before transfer (Table 4) .
Studies have implied a link between the frequency of peritonitis and the probability of EPS developing (10, 23) . For example, in a study from Japan, the frequency of peritonitis in patients who developed EPS was 3.3 times that in patients who did not; however, the authors observed that not all patients who developed EPS had a history of peritonitis (23) . Our data accords with those findings. We observed that the peritonitis rate was higher in patients who developed EPS, but that peritonitis was not a prerequisite for the development of EPS: 1 patient had no peritonitis episodes during 157 months on PD and still developed EPS (Table 4) .
Recent studies have suggested that icodextrin-based dialysis solution could affect peritoneal reactivity (24) . However, icodextrin-based solutions have not been reported as a risk factor for the development of EPS in several studies (3, 6, 7, 9) , and in our study, only 1 patient had been exposed to icodextrin before the development of EPS (Table 4) .
The present study is limited by its retrospective nature and by the lack of radiologic imaging for all patients. In most cases, clinical information had to be retrieved by chart review. Complete data concerning dextrose exposure and peritoneal equilibration testing were not available. The strength of the study lies in its status as a single-center study, in the strict criteria used to establish a diagnosis of EPS, and in the reading of radiographs by 2 experienced radiologists.
CONCLUSIONS
All patients maintained on PD for 5 or more years in a large urban center in the United States were examined for the presence of findings consistent with EPS. Among 76 long-term PD patients, 11 (14.5%) met ISPD criteria for EPS. Notably, in 25 of 38 patients (66%), abdominal CT findings were suggestive of a diagnosis of EPS, but in only 10 were the ISPD criteria for a diagnosis of EPS met. Thus, the presence of CT findings in the absence of clinical symptoms must be interpreted with caution.
Our observations should stimulate increased physician awareness of EPS as a long-term complication of PD therapy. Research to better define the factors responsible for EPS development is required.
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